Seminal suPAR Levels as Marker of Abacterial Male Accessory Gland Inflammation in Hypogonadism
| Autor: | Silvia Baroni, Francesca Mancini, Laura De Marinis, Andrea Urbani, Riccardo Marana, Alfredo Pontecorvi, Giuseppe Grande, Chiara Autilio, Cecilia Zuppi, Domenico Milardi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Infertility medicine.medical_specialty Hormone Replacement Therapy medicine.medical_treatment Prostatic Hyperplasia Prostatitis Systemic inflammation Biochemistry Receptors Urokinase Plasminogen Activator Male infertility 03 medical and health sciences 0302 clinical medicine Semen Structural Biology Internal medicine 0502 economics and business medicine Humans Testosterone 030219 obstetrics & reproductive medicine business.industry Hypogonadism 05 social sciences General Medicine Middle Aged medicine.disease Male accessory gland Endocrinology SuPAR 050211 marketing Androgen replacement therapy medicine.symptom business Biomarkers |
| Zdroj: | Protein & Peptide Letters. 25:478-482 |
| ISSN: | 0929-8665 |
| Popis: | BACKGROUND Recent evidences suggest that hypogonadism is an important risk factor for lower urinary tract symptoms and benign prostatic hyperplasia. Several papers have discussed the role of chronic inflammation in the development of BPH, which may be modulated by the hypogonadal state. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR), known protein marker of systemic inflammation, can be assayed in the seminal plasma and represents a reliable and sensitive marker of inflammation for the Male Accessory Gland Inflammation (MAGI). OBJECTIVE The aim of this study has been to investigate if seminal suPAR is elevated in MAGI with hypogonadism and if suPAR represent a useful marker of abacterial inflammation in hypogonadism. METHODS We included in the study twenty male patients aged between 25 and 55 year-old with secondary postsurgical hypogonadism. The same patients were also evaluated after a 3-month of Testosterone Replacement Therapy (TRT), to evaluate the effect of androgen replacement therapy on suPAR. Ten fertile men have been enrolled as a control group in the protocol. SuPAR concentrations were assayed on seminal plasma using an Enzyme-Linked Immunosorbent Assay (ELISA) kit. RESULTS Hypogonadic patients presented significantly increased levels of seminal suPAR respect to controls (86.1±36.8 vs 55.2±20.0 ng/mL, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|